drugset / Trial / NCT01516749

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749

Phase 2 Completed 6 enrolled University of California, San Francisco
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for relapse of HS.

Timeline

Start
2012-10
Primary completion
2013-05
Completion
2013-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous